Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR8028 ophthalmic solution for dry eye disease
CTR20210163Phase 3Completed
- Sponsor
- eVenus Pharmaceutical Laboratories
- Start
- Jan 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine in dry eye syndrome (DED) (2 arms), sponsored by eVenus Pharmaceutical Laboratories. Primary endpoints: Change from baseline in total corneal fluorescein staining (tCFS), Change from baseline in dryness score (VAS) and 5 more. Started Jan 2021; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20210163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210163.